A
Alfonso Tafur
Researcher at NorthShore University HealthSystem
Publications - 147
Citations - 5501
Alfonso Tafur is an academic researcher from NorthShore University HealthSystem. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 25, co-authored 131 publications receiving 3584 citations. Previous affiliations of Alfonso Tafur include Cardiovascular Institute of the South & University of Oklahoma Health Sciences Center.
Papers
More filters
Journal ArticleDOI
Prevention of Femoropopliteal In-Stent Restenosis With Cilostazol: A Meta-Analysis.
TL;DR: The use of cilostazol appears to prevent in-stent restenosis of high-risk patients, with good primary patency rates after endovascular stenting in patients with lower extremity arterial stenting.
Journal ArticleDOI
Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials.
Kirtipal Bhatia,Vardhmaan Jain,Devika Aggarwal,Muthiah Vaduganathan,Sameer Arora,Zeeshan Hussain,Guneesh Uberoi,Alfonso Tafur,Cen Zhang,Mark J. Ricciardi,Arman Qamar +10 more
Journal ArticleDOI
Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.
TL;DR: Results demonstrate that the measured anti-Xa activity alone does not fully reflect the overall biologic spectrum of these agents.
Journal ArticleDOI
Predictors of active cancer thromboembolic outcomes: RIETE experience of the Khorana score in cancer-associated thrombosis
Alfonso Tafur,Joseph A. Caprini,Lauren Cote,Javier Trujillo-Santos,Jorge Del Toro,F. García-Bragado,C. Tolosa,Giovanni Barillari,Adriana Visonà,Manuel Monreal,Riete Investigators +10 more
TL;DR: Most VTEs occur in patients with low or moderate risk scores, and the KRS did not accurately predict VTE recurrence, major bleeding, or mortality among patients with cancer-associated thrombosis.
Journal ArticleDOI
Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Fakiha Siddiqui,Alfonso Tafur,Lorenzo Storino Ramacciotti,Walter Jeske,Debra Hoppensteadt,Eduardo Ramacciotti,Omer Iqbal,Jawed Fareed +7 more
TL;DR: Recombinant coagulation factor Xa, inactivated Zh-zo, also known as andexanet alfa, is a modified version of human FXa that has been developed to neutralize FXa inhibitors but overshoots thrombogenesis in both the saline and FXa inhibitor supplemented systems.